

Summary

Production Name	WISP-3 Rabbit Polyclonal Antibody
Description	Rabbit Polyclonal Antibody
Host	Rabbit
Application	WB,IHC,ELISA
Reactivity	Human,Rat,Mouse

Performance

Conjugation	Unconjugated	
Modification	Unmodified	
lsotype	IgG	
Clonality	Polyclonal	
Form	Liquid	
Storago	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw	
Storage	cycles.	
Buffer	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.	
Purification	Affinity purification	

Immunogen

Gene Name	WISP3 CCN6 UNQ462/PRO790/PRO956
Alternative Names	WNT1-inducible-signaling pathway protein 3 (WISP-3) (CCN family member 6)
Gene ID	8838.0
SwissProt ID	O95389.The antiserum was produced against synthesized peptide derived from the N-
	terminal region of human WISP3. AA range:1-50

Application

Dilution Ratio	WB 1:500-2000, IHC 1:100 - 1:300. ELISA 1:10000-20000
Molecular Weight	55kD

Background

Product Name: WISP-3 Rabbit Polyclonal Antibody Catalog #: APRab19906



This gene encodes a member of the WNT1 inducible signaling pathway (WISP) protein subfamily, which belongs to the connective tissue growth factor (CTGF) family. WNT1 is a member of a family of cysteine-rich, glycosylated signaling proteins that mediate diverse developmental processes. The CTGF family members are characterized by four conserved cysteine-rich domains: insulin-like growth factor-binding domain, von Willebrand factor type C module, thrombospondin domain and C-terminal cystine knot-like domain. This gene is overexpressed in colon tumors. It may be downstream in the WNT1 signaling pathway that is relevant to malignant transformation. Mutations of this gene are associated with progressive pseudorheumatoid dysplasia, an autosomal recessive skeletal disorder, indicating that the gene is essential for normal postnatal skeletal growth and cartilage homeostasis. Multipledisease:Defects in WISP3 are the cause of progressive pseudorheumatoid arthropathy of childhood (PPAC) [MIM:208230]. PPAC is an autosomal recessive disorder characterized by stiffness and swelling of joints, motor weakness and joint contractures. Signs and symptoms of the disease develop typically between three and eight years of age. This progressive disease is a primary disorder of articular cartilage with continued cartilage loss and destructive bone changes with aging, function: Appears to be required for normal postnatal skeletal growth and cartilage homeostasis, similarity: Belongs to the CCN family, similarity: Contains 1 CTCK (C-terminal cystine knot-like) domain.,similarity:Contains 1 IGFBP N-terminal domain.,similarity:Contains 1 TSP type-1 domain.,tissue specificity:Predominant expression in adult kidney and testis and fetal kidney. Weaker expression found in placenta, ovary, prostate and small intestine. Also expressed in skeletally-derived cells such as synoviocytes and articular cartilage chondrocytes.,

Research Area

Image Data



Western blot analysis of Hela Cell Lysate using antibody. Secondary antibody was diluted at 1:20000





Immunohistochemical analysis of paraffin-embedded human-liver-cancer, antibody was diluted at 1:200

Note For research use only.